Introduction
The term sarcopenia is derived from the Greek word Σάρξ meaning "flesh" and Πενία (penia) meaning "poverty". It was described for the first time by Rosenberg in 1989 1, 2 , referring to age related loss of skeletal muscle mass 3 . However, over the last decades, there was no widely accepted definition of sarcopenia 4 . The European Working Group on Sarcopenia in Older People (EWGSOP) provided a definition of sarcopenia in 2010; "A combination of a progressive and generalized loss of skeletal muscle mass and muscle strength or physical performance, with high risk of adverse outcomes such as physical disability, poor quality of life and death" 5 . Sarcopenia is known to be a new geriatric syndrome 6 , as it mainly affects older people, aged 60-70 years, on an average of 5-13% 7 . It is reported that 5-13% of people over 60 years of ages have low muscle mass, while the average rises to 50% in patients over 80 years 8 . The decrease of muscle mass is accompanied with loss in muscle strength, aerobic capacity and metabolic rate that lead to reduced muscle function 9 . The percentages are higher as far as the decline in muscle strength during the ages is concerned 7 . Although sarcopenia affects mostly older people, it can also be present in young adults, from the fourth decade of life, according to a recent study by Cherin et al. (2014) 10 . Sarcopenia can be divided into two main categories; primary and secondary. Primary sarcopenia includes cases where aging is the only apparent reason for its clinical manifestation, whereas secondary sarcopenia includes cases where further pathologies coexist 11 . Secondary sarcopenia includes activity-related, diseaserelated, and nutrition-related sarcopenia 12 . The EWGSOP suggested the separation of sarcopenia in three stages: a) Pre-sarcopenia, which includes only low muscle mass, without any muscle strength or performance dysfunctions, b) Sarcopenia, which is defined as the presence of low muscle mass and low muscle strength or physical performance and c) Severe sarcopenia, which includes all three criteria 11 .
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Etiology of Sarcopenia
The development of sarcopenia is considered to be the result of several factors including the genetic background 13 , age related hormones 14 , nutrition [14] [15] [16] , neurodegeneration 5, 17 , chronic diseases 15, 18 and disability, immobility and lack of physical activity 19 .
Diagnostic Criteria
The first step towards the management of sarcopenia is the proper and professional diagnosis. According to EWGSOP the diagnosis of sarcopenia depends on the presence of low muscle mass (LMM) plus low muscle strength (LMS) or low physical performance (LPP) 20 .
Muscle mass
There are three available imaging techniques to estimate muscle mass. Dual energy x-ray absorptiometry (DXA) measures precisely the body composition 21 . Although, DXA may overestimate skeletal muscle due to the difficulty in distinguishing muscle from water retention. It is a cheap method but there is lack of equipment 14 .
The gold standard for measuring muscle mass is the Magnetic Resonance Imaging (MRI), without radiation exposure. Drawbacks of MRI are the high cost and the need of specialized staff and specific software, as well it is time consuming 22 . Computed Tomography (CT) is also very precise in measuring muscle mass, but not only it is an expensive method but also is associated with high radiation exposure 21 . Bioimpendance analysis estimates the volume of fat and lean body mass by dividing the skeletal muscle by the square of height 23 . Bioimpendance is easy to use, it can be used at the bedside without expose to radiation. But it is not very accurate, as it can be biased by the hydration status and the presence of edema 22 . Total body potassium (TBK) is another method for measuring skeletal muscle, as skeletal muscle contains approximately 50% of the total body potassium pool. Although, it is easy to use, it is not common 11 .
Muscle strength
Handgrip strength is a simple and very practical method of measuring muscle strength. The Jamar dynamometer is the most well-known device 24, 25 . Knee flexion/extensionis another way of estimating muscle strength either isometrically or isokinetally. However, it requires special equipment and staff.
Prevalence of Sarcopenia
Although, sarcopenia is mostly observed in older ages, it is still difficult to establish its prevalence 26 . This difficulty, as a consequence of the different diagnostic criteria, rises from the heterogeneity of the studied population 27 . Prevalence of sarcopenia in older people is estimated to range between 1 and 29%. This percentage increases for older people, aged over 80 years 26 . Higher prevalence of sarcopenia is observed in hospitalized elderly patients 27 .
In general, prevalence of sarcopenia depends on various parameters, such as: a) Sex, where men have higher prevalence as compared to women, b) Age, where older individuals tend to be more prevalent for sarcopenia, while this tendency decreases with decreasing age. Yet, in a recent report by Cherin P et al. (2014) 28 . Finally, sarcopenia has high prevalence in comorbidities. For instance, the presence of sarcopenia is raised to 58% in patients after a hip fracture surgery or for instance in patients after gastric cancer surgery 29, 30 .
Impact on public health

Direct impact
There is a lack of data concerning the impact of sarcopenia in the public health system. The only published study concerns the United States of America (USA), which may be representative for other developed countries. This research showed that in the USA the public health expenditure of sarcopenia is estimated to be 18.5$ billion, which is estimated to be divided to 8$ billion for males and 7.7$ billion for females in the year 2000.This expenditure corresponds to the 1.5% of total health care cost in the United States in 2000. It has been also reported that "… reducing the prevalence of sarcopenia by 10% would result in savings of 1.1$ billion per year in USA healthcare cost". Comparatively, it is worth mentioning that in the same year the total healthcare expenditure for osteoporotic fractures in the USA was 16.3$ billion 31 .
Indirect impact
Sarcopenia has also numerous negative outcomes that have a major impact on public health including consequences in personal level, in the social and health care system. Sarcopenia is related to many comorbidities, such as physical disability, high risk of falls, depression, hospitalization 32 bad quality of life, loss of productivity 33 and mortality. In particular, sarcopenia is linked with physical disability 34 that is associated with increased health care cost, more as outpatient. It has been estimated that over 75% of those will use home health services 35 . Sarcopenia is also associated with loss of impendence and inability of doing daily life activities 26, 27 . Sarcopenia is related with great risk of falls with the subsequent outcomes of it, which increase the health care cost 36 . Another indirect impact of sarcopenia on public health is the comorbidities that are associated with it. Sarcopenia usually coexist with osteoporosis and high risk of hip fracture 26, 27 . According to a recent study of Oliveira et al. (2015) , there is a significant association between sarcopenia and hip fractures 37 . The higher risk of fracture has as a consequence the increased risk of hospitalization, leading to a rise of health care expenditure 26 . Sarcopenia is also associated with other diseases and predicts poor outcomes is some of them. Endocrine diseases, especially diabetes, kidney diseases 26, 27 , coronary heart diseases are linked with sarcopenia and affect negatively the outcomes 18 . Sarcopenia, also, may interactively correlate with the presence and severity of age-related osteoarthritis 38 . It is also associated with high risk of poor outcomes in severe liver disease 39 . Sarcopenia is strongly linked with frailty, an age related syndrome which is characterized by lack of adaptive capacity of the organism 40 . Frailty is also associated with high risk of hospitalization and increased health care costs 41 .
In a recent study Sanchez-Rodríguez et al. using the ESPEN criteria for the definition of malnutrition and EWGSOP criteria for the definition of sarcopenia, drawn the conclusion that "…sarcopenia and malnutrition are related conditions, as most patients with sarcopenia fulfilled the ESPEN criteria for a diagnosis of malnutrition" 42 . Malnutrition is also one of the major factors of development age related diseases, such as sarcopenia. More specific, the cycle of frailty starts with chronic malnutrition, that in tern leads to sarcopenia. The health care cost of malnutrition must be taken into consideration in the cost and consequences of sarcopenia. Malnutrition affects every system of the human body, is both a cause and consequence of diseases and increases the risk of delaying recovery and poor outcomes, almost 70% are more likely for long-term stay in hospital, placing increased demans on hospital. All these lead to increased health care cost (Institute of Food and Health Policy 2009).
As it was mentioned before, frailty malnutrition and falls are associated with high risk of hospitalization. Moreover, sarcopenia its own presents also high risk of hospitalization. Poor physical condition leads to longer hospital stay for almost 20 days, that it means raise in health care cost 43 . Mortality is predicted to be higher in middle aged individuals and older adults suffering from sarcopenia 44 . A recent study confirmed that hospitalized patients with sarcopenia present a higher mortality rate as compared to hospitalized individuals without sarcopenia after one year postdischarge 14 . In addition, there is a strong association between the severity of sarcopenia and mortality 45 . As life expectancy increases, it is necessary for the public sector to invest to research for the prevention and treatment of sarcopenia. Public health expenditure and consequences of sarcopenia are considered to be direct and indirect. Up to date, expenditure estimation concerns the direct cost of sarcopenia, since the indirect cost is much complicated to be evaluated. Considering all these, is difficult to measure the real impact of sarcopenia on health care system.
